{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:35:28Z","timestamp":1767162928888,"version":"build-2238731810"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1351,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1111\/j.1742-1241.2011.02838.x","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T20:13:28Z","timestamp":1324412008000},"page":"132-138","source":"Crossref","is-referenced-by-count":7,"title":["Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study"],"prefix":"10.1155","volume":"66","author":[{"given":"D.-S.","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.-S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-S.","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,20]]},"reference":[{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0960-894X(00)00457-1","article-title":"Design and synthesis of piperidinyl piperidine analogues as potent and selective M2 muscarinic receptor antagonists","volume":"10","author":"Wang","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s007020050168","article-title":"Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14\u2003days administration of uncompetitive NMDA receptor antagonists","volume":"106","author":"Hesselink","year":"1999","journal-title":"J Neural Transm"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1532-5415.2000.tb04692.x","article-title":"Combined behavioral and drug therapy for urge incontinence in older women","volume":"48","author":"Burgio","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB7|cit7","first-page":"359","article-title":"Treatment of unstable bladder with oxybutynin hydrochloride. Our clinical experience in 80 cases","volume":"39","author":"Alladio","year":"1987","journal-title":"Minerva Urol Nefrol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02550355","article-title":"The use of oxybutynin in urological practice","volume":"19","author":"Kirkali","year":"1987","journal-title":"Int Urol Nephrol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group","volume":"161","author":"Anderson","year":"1999","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0090-4295(99)00259-9","article-title":"Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group","volume":"54","author":"Gleason","year":"1999","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0029-7844(99)00661-4","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group","volume":"95","author":"Versi","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00003495-200464080-00011","article-title":"Oxybutynin extended-release: a review of its use in the management of overactive bladder","volume":"64","author":"Siddiqui","year":"2004","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2490-10-15","article-title":"Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence","volume":"10","author":"Bodeker","year":"2010","journal-title":"BMC Urol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11934-003-0025-z","article-title":"Overactive bladder: improving the efficacy of anticholinergics by dose escalation","volume":"4","author":"MacDiarmid","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/01.ju.0000173076.93737.d5","article-title":"Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies","volume":"174","author":"MacDiarmid","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1128\/AEM.01112-10","article-title":"Recent emergence of clonal group O25b:K1:H4-B2-ST131 ibeA strains among Escherichia coli poultry isolates, including CTX-M-9-producing strains, and comparison with clinical human isolates","volume":"76","author":"Mora","year":"2010","journal-title":"Appl Environ Microbiol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nau.20110","article-title":"Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ)","volume":"24","author":"Matza","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00002018-200831060-00005","article-title":"Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study","volume":"31","author":"Michel","year":"2008","journal-title":"Drug Saf"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB19|cit19","first-page":"2217","article-title":"Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes","volume":"39","author":"Lind","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-2999(98)00214-3","article-title":"Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists","volume":"349","author":"Gillberg","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bjp.0701822","article-title":"Effects of tachykinin NK1 receptor antagonists on vagal hyperreactivity and neuronal M2 muscarinic receptor function in antigen challenged guinea-pigs","volume":"124","author":"Costello","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1464-410X.2009.08545.x","article-title":"Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome","volume":"104","author":"Chapple","year":"2009","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB23|cit23","article-title":"Comparative adherence to oxybutynin or tolterodine among older patients","author":"Gomes","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.juro.2009.11.026","article-title":"Overactive bladder medication adherence when medication is free to patients","volume":"183","author":"Sears","year":"2010","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/beog.1999.0079","article-title":"Quality of life and urinary incontinence","volume":"14","author":"Kelleher","year":"2000","journal-title":"Baillieres Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1191\/0962280204sm357ra","article-title":"Patient reported outcomes as endpoints in medical research","volume":"13","author":"Fairclough","year":"2004","journal-title":"Stat Methods Med Res"},{"key":"10.1111\/j.1742-1241.2011.02838.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","article-title":"Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment","volume":"68","author":"Brubaker","year":"2006","journal-title":"Urology"}],"updated-by":[{"DOI":"10.1111\/j.1742-1241.2012.02957.x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T00:00:00Z","timestamp":1337299200000}}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2011.02838.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2011.02838.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:08:28Z","timestamp":1643332108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2011.02838.x"}},"subtitle":["Prescription pattern and dose distribution of antimuscarinic"],"short-title":[],"issued":{"date-parts":[[2011,12,20]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02838.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12,20]]}}}